DAWEX
Dawex , the leading data exchange technology company, joins GAIA-X, the European federated data infrastructure. This European initiative aims to develop common requirements for a European data infrastructure, connecting infrastructures in order to turn them into a homogeneous, user-friendly system, strengthening also the ability to access, share and exchange data securely and confidently. By creating a proposal for the next generation of a data infrastructure for Europe, GAIA-X ambition is to provide a secure, federated system that meets the highest standards of digital independence while promoting innovation, and a new culture and understanding of data infrastructure interoperability.
Dawex has chosen to take part in this initiative in order to bring its Data Exchange expertise and a sustainable contribution to the development of a strong digital ecosystem in Europe. By joining GAIA-X, Dawex supports the acceleration of the development of a European data hub in a secure, trusted and compliant environment, taking into account the latest developments regarding regulations of personal and industrial/enterprise data, as well as the future European Data Governance Act .
Dawex Data Exchange technology allows public and private organizations to orchestrate data circulation, source, distribute and exchange data with stakeholders securely, in compliance with regulations. This technology is key to the development of European data ecosystems as promoted earlier this year by Thierry Breton, European Commissioner for Internal Market and Services. These data ecosystems will unlock the tremendous potential value of data that is currently untapped.
In June 2020, Dawex was named a “Technology Pioneer” by the World Economic Forum, contributing to the Data Policy work group to help define and implement forward-looking, interoperable, and trustworthy data policies to fuel innovation. By joining GAIA-X, a strong European ecosystem of tech players, Dawex brings an essential brick allowing all stakeholders involved in data exchanges to approach them at the same time on a technical, functional, business and regulatory level.
"Our mission is to provide cutting-edge data exchange technology that facilitates the circulation of data in a secure and trusted environment that complies with local and global regulations.” says Laurent Lafaye, co-CEO at Dawex. “This raises the central question of data infrastructure interoperability, which is essential to promote data access and data exchange to the largest number of companies in Europe.”
“GAIA-X initiative will foster the creation of data hubs that stimulate cross-sector innovation, create synergies, and allow the development of new use cases and business models.” says Fabrice Tocco, co-CEO of Dawex. “Dawex technology is very much aligned with this goal.”
About Dawex
Dawex , the leading data exchange technology company and the operator of the largest data marketplace, allows organizations to orchestrate data circulation, by sourcing and exchanging data securely, and in full compliance with regulations. Today 12,000+ organizations from 20+ sectors rely on Dawex Global Data Marketplace and Data Exchange Platform solutions to build their data exchange strategy. In 2020, Dawex is named Technology Pioneer by the World Economic Forum. Created in 2015, Dawex is a tech-company with offices in France and Canada, expanding business operations to Asia and the Middle East. More information on: www.dawex.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom